Examine the Significant Unmet Needs in the Non Small Cell Lung Cancer Market and Identify Opportunities for New Product Development
NSCLC comprises over 75% of all lung cancers. In 2006, more than 338,000 cases of the disease are expected to be diagnosed in the seven major pharmaceutical markets. High unmet needs still persist for this tumor type and despite two decades of extensive R&D and chemotherapy use, the median overall survival of NSCLC patient’s remains below 12 months.
This entry was posted on Tuesday, September 25th, 2007 at 9:44 am and is filed under Research, Non-Small-Cell. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.